Cogent Biosciences (COGT) News Today $4.69 -0.88 (-15.76%) Closing price 03:59 PM EasternExtended Trading$6.15 +1.46 (+31.07%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Cogent Biosciences Reports First Quarter 2025 Financial ResultsMay 6 at 8:00 AM | globenewswire.comCogent Biosciences, Inc. (NASDAQ:COGT) Shares Sold by Invesco Ltd.Invesco Ltd. lessened its stake in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 92.2% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 38,641 shares of the technology company's stock after sellMay 6 at 3:21 AM | marketbeat.comLeerink Partnrs Has Strong Forecast for COGT FY2026 EarningsCogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Research analysts at Leerink Partnrs raised their FY2026 earnings estimates for Cogent Biosciences in a report released on Monday, April 28th. Leerink Partnrs analyst A. Berens now anticipates that the technology company will post earnings ofMay 3 at 8:54 AM | marketbeat.comCogent Biosciences Sees Unusually High Options Volume (NASDAQ:COGT)May 3 at 2:56 AM | americanbankingnews.comFY2026 EPS Estimate for Cogent Biosciences Lifted by AnalystMay 2, 2025 | americanbankingnews.comCogent Biosciences (COGT) to Release Quarterly Earnings on TuesdayCogent Biosciences (NASDAQ:COGT) will be releasing its Q1 2025 earnings before the market opens on Tuesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-6-cogent-biosciences-inc-stock-1/)May 1, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Trading 3.8% Higher - Here's What HappenedCogent Biosciences (NASDAQ:COGT) Trading 3.8% Higher - What's Next?April 30, 2025 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Shares Bought by Nantahala Capital Management LLCNantahala Capital Management LLC increased its holdings in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 7.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 852,855 shares of the technology company's stock after buying an additional 61,919 sharesApril 30, 2025 | marketbeat.comAnalysts Set Cogent Biosciences, Inc. (NASDAQ:COGT) Price Target at $14.43April 29, 2025 | americanbankingnews.comRenaissance Technologies LLC Makes New Investment in Cogent Biosciences, Inc. (NASDAQ:COGT)Renaissance Technologies LLC bought a new position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 242,929 shares of the technology compApril 28, 2025 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Shares Acquired by Adage Capital Partners GP L.L.C.Adage Capital Partners GP L.L.C. increased its position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 5.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,300,000 shares of the technology compApril 27, 2025 | marketbeat.comCogent Biosciences appoints Ray Frost as SVP, Market AccessApril 26, 2025 | markets.businessinsider.comCogent to present preclinical data from pipeline programs at AACR meetingApril 26, 2025 | markets.businessinsider.comCogent Biosciences, Inc. (NASDAQ:COGT) Receives Consensus Rating of "Moderate Buy" from BrokeragesCogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight ratings firms that are covering the company, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, four have assigned aApril 26, 2025 | marketbeat.comCogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New LeadersApril 25, 2025 | globenewswire.comSilverarc Capital Management LLC Has $7.19 Million Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT)Silverarc Capital Management LLC cut its stake in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 24.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 921,137 shares of the technology company's stock aftApril 24, 2025 | marketbeat.comDiadema Partners LP Acquires New Position in Cogent Biosciences, Inc. (NASDAQ:COGT)Diadema Partners LP purchased a new stake in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The fund purchased 90,000 shares of the technology company's stock, valued at approximately $702,000. Diadema Partners LP owApril 24, 2025 | marketbeat.comXTX Topco Ltd Takes $457,000 Position in Cogent Biosciences, Inc. (NASDAQ:COGT)XTX Topco Ltd acquired a new position in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 58,560 shares of the technology company's stock, valued at appApril 23, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Trading Down 7.6% - Should You Sell?Cogent Biosciences (NASDAQ:COGT) Trading Down 7.6% - Here's WhyApril 18, 2025 | marketbeat.comWalleye Capital LLC Boosts Stock Position in Cogent Biosciences, Inc. (NASDAQ:COGT)Walleye Capital LLC lifted its position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 68.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 936,791 shares of the technApril 18, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Shares Up 6.1% - Time to Buy?Cogent Biosciences (NASDAQ:COGT) Stock Price Up 6.1% - Still a Buy?April 17, 2025 | marketbeat.comAlliancebernstein L.P. Buys 382,882 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)Alliancebernstein L.P. lifted its position in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 466.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 464,942 shares of the technology companyApril 16, 2025 | marketbeat.comFmr LLC Boosts Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT)Fmr LLC grew its position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 99.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,569,256 shares of the technology company's stocApril 15, 2025 | marketbeat.comVanguard Group Inc. Purchases 418,975 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)Vanguard Group Inc. grew its position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 7.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,133,380 shares of the technology company's stock after buyiApril 14, 2025 | marketbeat.comTrexquant Investment LP Grows Stock Holdings in Cogent Biosciences, Inc. (NASDAQ:COGT)Trexquant Investment LP boosted its holdings in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 184.4% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 277,523 shares of the technology company's stock after buying an additional 179,9April 11, 2025 | marketbeat.comFranklin Resources Inc. Raises Stake in Cogent Biosciences, Inc. (NASDAQ:COGT)Franklin Resources Inc. boosted its holdings in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 28.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,283,673 shares of the technology company's stock after buyApril 11, 2025 | marketbeat.comCogent: Several 2025 Readouts On Deck With Bezuclastinib AdvancementApril 9, 2025 | seekingalpha.comCogent Biosciences (NASDAQ:COGT) Sets New 52-Week Low - Time to Sell?Cogent Biosciences (NASDAQ:COGT) Reaches New 52-Week Low - Time to Sell?April 9, 2025 | marketbeat.comSpringhill Fund Asset Management HK Co Ltd Takes $4.28 Million Position in Cogent Biosciences, Inc. (NASDAQ:COGT)Springhill Fund Asset Management HK Co Ltd acquired a new position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 548,554 shares of the technology company'April 8, 2025 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Shares Sold by Cinctive Capital Management LPCinctive Capital Management LP trimmed its stake in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 87.7% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 40,643 shares of the technology company's stock after selling 289,776 shares during the qApril 6, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Reaches New 52-Week Low - Here's WhyCogent Biosciences (NASDAQ:COGT) Hits New 52-Week Low - What's Next?April 2, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Stock Price Down 7.7% - Time to Sell?Cogent Biosciences (NASDAQ:COGT) Shares Down 7.7% - Should You Sell?April 1, 2025 | marketbeat.comCogent Biosciences, Inc. (NASDAQ:COGT) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Cogent Biosciences, Inc. (NASDAQ:COGT - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight analysts that are covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, four have issued a buy recMarch 31, 2025 | marketbeat.comWe're Keeping An Eye On Cogent Biosciences' (NASDAQ:COGT) Cash Burn RateMarch 29, 2025 | finance.yahoo.comEntryPoint Capital LLC Acquires Shares of 52,346 Cogent Biosciences, Inc. (NASDAQ:COGT)EntryPoint Capital LLC bought a new position in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 52,346 shares of the technology company's stock, valued at approximately $408,000. Other large investors havMarch 27, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Shares Down 5.1% - Here's WhyCogent Biosciences (NASDAQ:COGT) Trading Down 5.1% - What's Next?March 26, 2025 | marketbeat.comCogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual MeetingMarch 25, 2025 | globenewswire.comCogent Biosciences (NASDAQ:COGT) Shares Down 2.3% - Should You Sell?Cogent Biosciences (NASDAQ:COGT) Stock Price Down 2.3% - Should You Sell?March 15, 2025 | marketbeat.comScotiabank Initiates Coverage of Cogent Biosciences (COGT) with Sector Outperform RecommendationMarch 8, 2025 | msn.comCogent Biosciences (NASDAQ:COGT) Shares Down 5.3% - Should You Sell?Cogent Biosciences (NASDAQ:COGT) Stock Price Down 5.3% - Time to Sell?March 8, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Coverage Initiated at ScotiabankScotiabank started coverage on shares of Cogent Biosciences in a research note on Friday. They set a "sector outperform" rating and a $17.00 price target for the company.March 8, 2025 | marketbeat.comPiper Sandler Sticks to Their Buy Rating for Cogent Biosciences (COGT)March 7, 2025 | markets.businessinsider.comCogent Biosciences Announces Participation in the Leerink Healthcare ConferenceMarch 7, 2025 | globenewswire.comY Intercept Hong Kong Ltd Purchases 43,472 Shares of Cogent Biosciences, Inc. (NASDAQ:COGT)Y Intercept Hong Kong Ltd grew its holdings in Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) by 137.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 75,037 shares of the technology company's stock after purchasing an aMarch 2, 2025 | marketbeat.comCogent Biosciences (NASDAQ:COGT) Stock Price Up 7.8% - What's Next?Cogent Biosciences (NASDAQ:COGT) Shares Up 7.8% - Time to Buy?February 28, 2025 | marketbeat.comRobert W. Baird Lowers Cogent Biosciences (NASDAQ:COGT) Price Target to $8.00Robert W. Baird cut their price objective on Cogent Biosciences from $10.00 to $8.00 and set a "neutral" rating for the company in a research note on Thursday.February 28, 2025 | marketbeat.comCogent Biosciences announces expanded results from OLE portion of SUMMIT trialFebruary 27, 2025 | markets.businessinsider.comCogent Biosciences price target lowered to $8 from $10 at BairdFebruary 27, 2025 | markets.businessinsider.comCogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis PatientsFebruary 27, 2025 | globenewswire.comWedbush Research Analysts Boost Earnings Estimates for COGTCogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Equities research analysts at Wedbush lifted their Q1 2025 earnings estimates for shares of Cogent Biosciences in a research report issued to clients and investors on Tuesday, February 25th. Wedbush analyst D. Nierengarten now anticipates thaFebruary 27, 2025 | marketbeat.com Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Email Address COGT Media Mentions By Week COGT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COGT News Sentiment▼0.720.69▲Average Medical News Sentiment COGT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COGT Articles This Week▼133▲COGT Articles Average Week Get Cogent Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for COGT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ACADIA Pharmaceuticals News Metsera News Alvotech News Apellis Pharmaceuticals News Amneal Pharmaceuticals News Denali Therapeutics News Biohaven News Organon & Co. News NewAmsterdam Pharma News Ascentage Pharma Group International News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:COGT) was last updated on 5/6/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredREVEALED: Elon’s Secret Master Plan “AGENDA X”REVEALED: Elon's Secret Master Plan "AGENDA X" For almost 30 years, Elon worked on his master plan in secre...Brownstone Research | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump's $500B plan is fueling these monthly dividendsSomething extraordinary happened just 24 hours after Trump returned to office... He signed a document that ...Investors Alley | SponsoredConfidential Economic AdvisoryI've hesitated for months to record this video. The very act of sharing these details makes me deeply uncom...InvestorPlace | SponsoredThe New ElonThe New Face of DOGE? There is now a new, powerful and controversial figure at the heart of the DOGE agenda...Altimetry | SponsoredOur #1 Defense Stock for MayWe've already lost 18 straight simulated war games against China. The good news is, the U.S. military has a...Behind the Markets | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cogent Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cogent Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
